The Effects of Nabilone on Sleep in Fibromyalgia: Results of a Randomized Controlled Trial
The DOI matches its Crossref record; 30 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Sleep disorders affect many patients with chronic pain conditions. Cannabis has been reported by several patient populations to help sleep. We evaluated the safety and efficacy of nabilone, a synthetic cannabinoid, on sleep disturbance in fibromyalgia (FM), a disease characterized by widespread chronic pain and insomnia. METHODS: We conducted a randomized, double-blind, active-control, equivalency crossover trial to compare nabilone (0.5-1.0 mg before bedtime) to amitriptyline (10-20 mg before bedtime) in patients with FM with chronic insomnia. Subjects received each drug for 2 wk with a 2-wk washout period. The primary outcome was sleep quality, measured by the Insomnia Severity Index and the Leeds Sleep Evaluation Questionnaire. Secondary outcomes included pain, mood, quality of life, and adverse events (AEs). RESULTS: Thirty-one subjects were enrolled and 29 completed the trial (26 women, mean age 49.5 yr). Although sleep was improved by both amitriptyline and nabilone, nabilone was superior to amitriptyline (Insomnia Severity Index difference = 3.2; 95% confidence interval = 1.2-5.3). Nabilone was marginally better on the restfulness (Leeds Sleep Evaluation Questionnaire difference = 0.5 [0.0-1.0]) but not on wakefulness (difference = 0.3 [-0.2 to 0.8]). No effects on pain, mood, or quality of life were observed. AEs were mostly mild to moderate and were more frequent with nabilone. The most common AEs for nabilone were dizziness, nausea, and dry mouth. CONCLUSIONS: Nabilone is effective in improving sleep in patients with FM and is well tolerated. Low-dose nabilone given once daily at bedtime may be considered as an alternative to amitriptyline. Longer trials are needed to determine the duration of effect and to characterize long-term safety.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“RCTs using active comparators are lacking, except in two studies.15,20”
From Nabilone for the Management of Pain (2016) · cites this paper as [20]
In the citing paper
“It is important to note, however, that these low doses improved the primary outcome of sleep quality.”
From Nabilone for the Management of Pain (2016) · cites this paper as [20]
In the citing paper
“No between-group differences in pain were observed, which may be explained in part by the once-daily dosing strategy and relatively low doses used.”
From Nabilone for the Management of Pain (2016) · cites this paper as [20]
In the citing paper
“No statistical analysis, however, was conducted.15,20”
From Nabilone for the Management of Pain (2016) · cites this paper as [20]
In the citing paper
“When compared with dihydrocodeine and amitriptyline, patients receiving nabilone had a higher overall occurrence of ADRs.15,20”
From Nabilone for the Management of Pain (2016) · cites this paper as [20]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The american college of rheumatology 1990 criteria for the classification of fibromyalgia
Wolfe, F., Smythe, H. A., Yunus, M. B., Bennett, R. M., Bombardier, C., Goldenberg, D. L., Tugwell, P., Campbell, S. M., Abeles, M., Clark, P., et al. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330203 · Cited by 9,563
Validation of the Insomnia Severity Index as an outcome measure for insomnia research
Bastien, C. (2001) · Sleep Medicine · doi:10.1016/s1389-9457(00)00065-4 · Cited by 8,067 · cited 1×
“The ISI is a reliable and valid instrument used to quantify perceived insomnia severity and is used as an outcome measure in insomnia treatment research.(21) A score of 8 on the ISI implies no clinical insomnia, 8–14 implies moderate insomnia, and 15 implies severe insomnia.”
MethodThe short-form McGill pain questionnaire
Melzack, R. (1987) · Pain · doi:10.1016/0304-3959(87)91074-8 · Cited by 4,368
Wolfe, F., Ross, K., Anderson, J., Russell, I. J., & Hebert, L. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380104 · Cited by 2,416
(1991) · PubMed · Cited by 1,837
Management of fibromyalgia syndrome
Goldenberg, D. L. (2004) · JAMA · doi:10.1001/jama.292.19.2388 · Cited by 850 · cited 1×
“exercise, cognitive behavioral therapy, and patient education.(16,17) Nabilone, a synthetic cannabinoid, has been observed in a small case series to improve sleep in patients with chronic pain.”
BackgroundShort Form of the Profile of Mood States (POMS-SF): Psychometric information.
Curran, S. L., Andrykowski, M. A., & Studts, J. L. (1995) · Psychological Assessment · doi:10.1037//1040-3590.7.1.80 · Cited by 808
Crofford, L. J., Rowbotham, M. C., Mease, P. J., Russell, I. J., Dworkin, R. H., Corbin, A. E., Young, J. P., LaMoreaux, L. K., Martin, S. A., Sharma, U., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20983 · Cited by 654
White, K. P., Speechley, M. R., Harth, M., & Østbye, T. (1999) · PubMed · Cited by 410
Fibromyalgia patients show an abnormal dopamine response to pain
Wood, P. B., Schweinhardt, P., Jaeger, E., Dagher, A., Hakyemez, H., Rabiner, E. A., Bushnell, M. C., & Chizh, B. A. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05623.x · Cited by 406
Cited by
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169
Häuser, W., Ablin, J., Fitzcharles, M.-A., Littlejohn, G., Luciano, J. V., Usui, C., & Walitt, B. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.22 · Cited by 505
Self-citationCannabis, Cannabinoids, and Sleep: a Review of the Literature
Babson, K. A., Sottile, J., & Morabito, D. (2017) · Current Psychiatry Reports · doi:10.1007/s11920-017-0775-9 · Cited by 484
Stockings, E., Campbell, G., Hall, W. D., Nielsen, S., Zagic, D., Rahman, R., Murnion, B., Farrell, M., Weier, M., & Degenhardt, L. (2018) · Pain · doi:10.1097/j.pain.0000000000001293 · Cited by 460
Fitzcharles, M.-A., Ste-Marie, P. A., Goldenberg, D. L., Pereira, J. X., Abbey, S., Choinière, M., Ko, G., Moulin, D. E., Panopalis, P., Proulx, J., et al. (2013) · Pain Research and Management · doi:10.1155/2013/918216 · Cited by 409
Self-citationSex-Dependent Effects of Cannabis and Cannabinoids: A Translational Perspective
Cooper, Z. D., & Craft, R. M. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.140 · Cited by 350
“…or cannabinoids have also been demonstrated in multiple sclerosis patients (Notcutt, 2015), and cannabinoids may be useful for the treatment of other auto-immune disorders such as rheumatoid arthritis, fibromyalgia, and Crohn’s disease (Ware et al, 2010; Katchan et al, 2016; Katz et al, 2016).”
BackgroundThe Therapeutic Potential of Cannabis and Cannabinoids
Grotenhermen, F., & Müller-Vahl, K. (2012) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2012.0495 · Cited by 307
Donvito, G., Nass, S. R., Wilkerson, J. L., Curry, Z. A., Schurman, L. D., Kinsey, S. G., & Lichtman, A. H. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.204 · Cited by 301
Fibromyalgia Pathogenesis and Treatment Options Update
Chinn, S., Caldwell, W., & Gritsenko, K. (2016) · Current Pain and Headache Reports · doi:10.1007/s11916-016-0556-x · Cited by 296
Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals
Legare, C. A., Raup-Konsavage, W. M., & Vrana, K. E. (2022) · Pharmacology · doi:10.1159/000521683 · Cited by 275
Pergam, S. A., Woodfield, M. C., Lee, C. M., Cheng, G., Baker, K. K., Marquis, S. R., & Fann, J. R. (2017) · Cancer · doi:10.1002/cncr.30879 · Cited by 267
“1-3 (no change) 65 (30) 177 (47) 213 (69)”
BackgroundOpioid-Sparing Effect of Cannabinoids: A Systematic Review and Meta-Analysis
Nielsen, S., Sabioni, P., Trigo, J. M., Ware, M. A., Betz-Stablein, B. D., Murnion, B., Lintzeris, N., Khor, K. E., Farrell, M., Smith, A., et al. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.51 · Cited by 265
Self-citationBaron, E. P. (2015) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.12570 · Cited by 206
One year in review 2021: fibromyalgia
Alciati, A., Nucera, V., Masala, I. F., Giallanza, M., La Corte, L., Giorgi, V., Sarzi-Puttini, P., & Atzeni, F. (2021) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/gz4i3i · Cited by 200
“pared nabilone to amitriptyline (10 mg) in treating insomnia in FM patients, finding no significant improvement in pain, mood, or quality of life in the nabilone group (44).”
BackgroundHäuser, W., Finn, D. P., Kalso, E., Krcevski‐Skvarc, N., Kress, H., Morlion, B., Perrot, S., Schäfer, M., Wells, C., & Brill, S. (2018) · European Journal of Pain · doi:10.1002/ejp.1297 · Cited by 199
Lynch, M. E., & Ware, M. A. (2015) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-015-9600-6 · Cited by 195
“…in fibromyalgia (N = 29/32), both agents improved sleep with nabilone demonstrating significantly more improvement in sleep quality on one of the sleep measures; there was no significant impact on pain, however subjects started with a relatively low mean pain score of 2.3/10 (Ware et al. 2010).”
BackgroundInfluentialSelf-citationRusso, E. B. (2016) · Cannabis and Cannabinoid Research · doi:10.1089/can.2016.0009 · Cited by 190
Review of pharmacological therapies in fibromyalgia syndrome
Häuser, W., Walitt, B., Fitzcharles, M.-A., & Sommer, C. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4441 · Cited by 188
“In the second study, nabilone was superior to placebo after 4 weeks in 40 patients for both pain and quality of life [42].”
BackgroundSelf-citationBilbao, A., & Spanagel, R. (2022) · BMC Medicine · doi:10.1186/s12916-022-02459-1 · Cited by 181
Toth, C., Mawani, S., Brady, S., Chan, C., Liu, C., Mehina, E., Garven, A., Bestard, J., & Korngut, L. (2012) · Pain · doi:10.1016/j.pain.2012.06.024 · Cited by 174
“Clinical trials of cannabinoids in chronic pain disorders have also reported improved sleep as either a primary or secondary outcome measure [39,46].”
BackgroundMethodSuraev, A. S., Marshall, N. S., Vandrey, R., McCartney, D., Benson, M. J., McGregor, I. S., Grunstein, R. R., & Hoyos, C. M. (2020) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2020.101339 · Cited by 161
Fibromyalgia: Recent Advances in Diagnosis, Classification, Pharmacotherapy and Alternative Remedies
Maffei, M. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217877 · Cited by 150
“Nabilone was also effective in improving sleep [50]; however, participants taking nabilone experienced more adverse events (such as dizziness/drowsiness, dry mouth and vertigo) than did participants taking placebo or amitriptyline (see below).”
ResultFitzcharles, M., Baerwald, C., Ablin, J. N., & Häuser, W. (2016) · Der Schmerz · doi:10.1007/s00482-015-0084-3 · Cited by 178
“Studies enrolled adult participants of mean age ranging between 26 and 76 years, with upper limit of 75 years in one study [39] and no upper age limit in the other study [48].”
BackgroundMethodResultInfluentialSelf-citationHUSAK, A., & Bair, M. J. (2020) · Pain Medicine · doi:10.1093/pm/pnz343 · Cited by 170
Chen, Q., Hayman, L. L., Shmerling, R. H., Bean, J. F., & Leveille, S. G. (2011) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2011.03544.x · Cited by 139
“In contrast, a study on the use of a synthetic cannabinoid improved sleep in people with fibromyalgia but had no effect on pain.(46) Research is needed to determine whether better management of more-severe or -disseminated pain conditions in older adults also leads to better sleep.”
BackgroundCannabinoids and autoimmune diseases: A systematic review
Katchan, V., David, P., & Shoenfeld, Y. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.02.008 · Cited by 171
Cannabinoids, Endocannabinoids and Sleep
Kesner, A. J., & Lovinger, D. M. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00125 · Cited by 151
Fiz, J., Durán, M., Capellà, D., Carbonell, J., & Farré, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018440 · Cited by 133
“Three clinical trials have suggested the possible benefit of cannabinoid in the management of FM [6–8].”
BackgroundMethodThe endocannabinoid system in pain and inflammation: Its relevance to rheumatic disease
Barrie, N., & Manolios, N. (2017) · European Journal of Rheumatology · doi:10.5152/eurjrheum.2017.17025 · Cited by 153
“In studies examining the endocannabinoid-based drug “Nabilone” on pain outcomes in fibromyalgia, the statistically significant effects were outweighed when side effects were taken into consideration (78-80).”
BackgroundSafety and Efficacy of Medical Cannabis in Fibromyalgia
Sagy, I., Bar-Lev Schleider, L., Abu-Shakra, M., & Novack, V. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8060807 · Cited by 130
“The authors found a moderate effect on insomnia, but not on other aspects of sleep, in addition to no improvement in pain and quality of life [11].”
BackgroundAntidepressants for pain management in adults with chronic pain: a network meta-analysis
Birkinshaw, H., Friedrich, C., Cole, P., Eccleston, C., Serfaty, M. A., Stewart, G. B., White, S. P., Moore, A., Phillippo, D., & Pincus, T. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014682.pub2 · Cited by 222
The effects of cannabinoid administration on sleep: a systematic review of human studies
Gates, P., Albertella, L., & Copeland, J. (2014) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2014.02.005 · Cited by 147
“Country of origin Cannabis type administered Cannabis dose and duration Comparisons made (effectiveness of blinding) Sleep measure Experimental/statistical controls Participant detailsa (total N) Outcome Babor et al. 1976 [34] 42.4 US 2% THC in a 1g joint 21 d with monitored access; typical use was 2.6 (0.9) joints/d,…”
BackgroundInfluentialCurrent and Emerging Pharmacotherapy for Fibromyalgia
Tzadok, R., & Ablin, J. N. (2020) · Pain Research and Management · doi:10.1155/2020/6541798 · Cited by 122
An Analysis of Applicants Presenting to a Medical Marijuana Specialty Practice in California
Nunberg, H., Kilmer, B., Pacula, R. L., & Burgdorf, J. R. (2011) · Journal of Drug Policy Analysis · doi:10.2202/1941-2851.1017 · Cited by 121
“Similarly, Ware et al. (2010) concluded that nabilone “is effective in improving sleep in patients with fibromyalgia and is well tolerated.””
Cannabis in Pain Treatment: Clinical and Research Considerations
Savage, S. R., Romero-Sandoval, A. E., Schatman, M. E., Wallace, M. S., Fanciullo, G. J., McCarberg, B. H., & Ware, M. A. (2016) · Journal of Pain · doi:10.1016/j.jpain.2016.02.007 · Cited by 135
“ated with pain, including: spasticity associated with multiple sclerosis or stroke,(12,46) anxiety and post-traumatic stress disorder,(67) nausea and vomiting,(56) cachexia,(31) inflammatory bowel diseases,(61) migraine,(58) and sleep disturbance.(79,99) Patients with pain may elect cannabis use for these symptoms as…”
BackgroundSelf-citationTargeting Endocannabinoid Signaling: FAAH and MAG Lipase Inhibitors
van Egmond, N., Straub, V. M., & van der Stelt, M. (2021) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-030220-112741 · Cited by 122
“Beneficial effects have been observed in chronic neuropathic pain both related and unrelated to MS (26) and in inflammatory pain (27, 28).”
BackgroundWalitt, B., Klose, P., Fitzcharles, M.-A., Phillips, T., & Häuser, W. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011694.pub2 · Cited by 120
Self-citationAn update on pharmacotherapy for the treatment of fibromyalgia
Calandre, E. P., Rico-Villademoros, F., & Slim, M. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1047343 · Cited by 119
“(2010) [107] Double-blind, crossover NBN versus AMT (n = 32) NBN: 0.”
BackgroundInfluentialPassie, T., Emrich, H. M., Karst, M., Brandt, S. D., & Halpern, J. H. (2012) · Drug Testing and Analysis · doi:10.1002/dta.1377 · Cited by 117
“studies showed THC and cannabis to be effective in sleep disorders and that they were well tolerated([127]) and a low nabilone (THC) dose given once per day at bedtime was suggested as a possible alternative to amitriptyline.([128]) No tolerance on pain or sleep, nor a need for dosage increases have been observed.”
BackgroundCannabis and Cannabinoids for Chronic Pain
Romero-Sandoval, E. A., Kolano, A. L., & Alvarado-Vazquez, P. A. (2017) · Current Rheumatology Reports · doi:10.1007/s11926-017-0693-1 · Cited by 154
The use of cannabinoids for sleep: A critical review on clinical trials.
Kuhathasan, N., Dufort, A., MacKillop, J., Gottschalk, R., Minuzzi, L., & Frey, B. N. (2019) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000285 · Cited by 104
Effects of Cannabinoids on Sleep and their Therapeutic Potential for Sleep Disorders
Kaul, M., Zee, P. C., & Sahni, A. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01013-w · Cited by 126
AminiLari, M., Wang, L., Neumark, S., Adli, T., Couban, R., Giangregorio, A., Carney, C. E., & Busse, J. W. (2021) · SLEEP · doi:10.1093/sleep/zsab234 · Cited by 116
Cannabinoid derivatives and the pharmacological management of pain
Lessa, M. A., Cavalcanti, I. L., & Figueiredo, N. V. (2016) · Revista Dor · doi:10.5935/1806-0013.20160012 · Cited by 111
Role of Cannabinoids in the Treatment of Pain and (Painful) Spasticity
Karst, M., Wippermann, S., & Ahrens, J. (2010) · Drugs · doi:10.2165/11585260-000000000-00000 · Cited by 104
Fitzcharles, M., Ste‐Marie, P. A., Häuser, W., Clauw, D. J., Jamal, S., Karsh, J., Landry, T., LECLERCQ, S. A., McDougall, J. J., Shir, Y., et al. (2015) · Arthritis Care & Research · doi:10.1002/acr.22727 · Cited by 100
Self-citation(2014) · Handbook of Clinical Neurology · doi:10.1016/b978-0-7020-4086-3.00033-3 · Cited by 86
Uso terapêutico dos canabinoides em psiquiatria
Crippa, J. A. S., Zuardi, A. W., & Hallak, J. E. C. (2010) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462010000500009 · Cited by 85
Insomnia Severity Index: A reliability generalisation meta‐analysis
Cerri, L., Justo, M. C., Clemente, V., Gomes, A. A., Pereira, A., & Marques, D. R. (2023) · Journal of Sleep Research · doi:10.1111/jsr.13835 · Cited by 105
“…situation, such as in cancerology (Sharpley et al., 2021), in mild traumatic brain injury events (Luethcke et al., 2011), in pain medicine, such as patients suffering from fibromyalgia (Ware et al., 2010), and in the regulation of sleep-related side effects of menopause (Sternfeld et al., 2014).”
Bestard, J. A., & Toth, C. C. (2011) · Pain Practice · doi:10.1111/j.1533-2500.2010.00427.x · Cited by 76
“Parameters of sleep improved among patient groups receiving either nabilone or gabapentin.(24,25) Sleep disturbance, which was greater among intervention groups as compared with the control (no therapy) group, improved in all intervention groups as well.”
BackgroundMedikamentöse Therapie des Fibromyalgiesyndroms: Systematische Übersicht und Metaanalyse
Sommer, C., Häuser, W., Alten, R., Petzke, F. W., Späth, M., Tölle, T. R., Üçeyler, N., Winkelmann, A., Winter, E., & Bär, K. (2012) · Der Schmerz · doi:10.1007/s00482-012-1172-2 · Cited by 86
Nabilone for the Management of Pain
Tsang, C. C., & Giudice, M. G. (2016) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1709 · Cited by 73
“A crossover, double-blind RCT compared nabilone and amitriptyline as adjunctive therapy in patients with fibromyalgia.(20) Adult patients with a diagnosis of fibromyalgia and self-reported chronic insomnia were included.”
MethodSafety Considerations in Cannabinoid-Based Medicine
Gottschling, S., Ayonrinde, O., Bhaskar, A., Blockman, M., D’Agnone, O., Schecter, D., Rodríguez, L. D. S., Yafai, S., & Cyr, C. (2020) · International Journal of General Medicine · doi:10.2147/ijgm.s275049 · Cited by 73
Management of Fibromyalgia Syndrome in 2016
Okifuji, A., Gao, J., Bokat, C. E., & Hare, B. D. (2016) · Pain Management · doi:10.2217/pmt-2016-0006 · Cited by 76
Cannabinoids for the treatment of rheumatic diseases — where do we stand?
Katz, D., Katz, I., Porat-Katz, B.-S., & Shoenfeld, Y. (2018) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0025-5 · Cited by 69
Therapeutic Uses of Cannabis on Sleep Disorders and Related Conditions
Choi, S., Huang, B. C., & Gamaldo, C. E. (2019) · Journal of Clinical Neurophysiology · doi:10.1097/wnp.0000000000000617 · Cited by 61
Parmar, J. R., Forrest, B. D., & Freeman, R. A. (2015) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2015.09.002 · Cited by 62
Perry, R., Leach, V., Davies, P., Penfold, C., Ness, A., & Churchill, R. (2017) · Systematic Reviews · doi:10.1186/s13643-017-0487-6 · Cited by 57
“Also, a meta-analysis of two RCTs and one CCT [36, 38, 40] (n = 97) favoured homoeopathy in pain intensity using a 100-mm VAS (SMD= −0.54: 95% CI −0.97 to −0.10, P = 0.02; I2 = 42%), compared to placebo.”
BackgroundMethodInfluentialThe current treatment of fibromyalgia
Júnior, J. O. D. O., & de Almeida, M. B. (2018) · Brazilian Journal Of Pain · doi:10.5935/2595-0118.20180049 · Cited by 97
Boehnke, K. F., Gagnier, J. J., Matallana, L. K., & Williams, D. A. (2021) · Journal of Pain · doi:10.1016/j.jpain.2021.04.011 · Cited by 65
Cannabis in Palliative Medicine: Improving Care and Reducing Opioid-Related Morbidity
Carter, G. T., Flanagan, A. M., Earleywine, M., Abrams, D. I., Aggarwal, S. K., & Grinspoon, L. (2011) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/1049909111402318 · Cited by 65
“These compounds further improved the efficacy of cannabis.(102-104) With simple trial and error, most patients are able to get the right combination of cannabinoids that meet their needs.”
BackgroundCannabinoids in the Treatment of Insomnia Disorder: A Systematic Review and Meta-Analysis
Bhagavan, C., Kung, S. M., Doppen, M., John, M., Vakalalabure, I., Oldfield, K., Braithwaite, I. E., & Newton‐Howes, G. (2020) · CNS Drugs · doi:10.1007/s40263-020-00773-x · Cited by 61
Fibromyalgia and Inflammation: Unrevealing the Connection
García‐Domínguez, M. (2025) · Cells · doi:10.3390/cells14040271 · Cited by 80
Role of Cannabinoids in Pain Management
Russo, E. B., & Hohmann, A. G. (2012) · Springer eBooks · doi:10.1007/978-1-4614-1560-2_18 · Cited by 70
Velayudhan, L., McGoohan, K., & Bhattacharyya, S. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003524 · Cited by 58
“All except 4 studies used placebo control [43,45,54,62].”
MethodResultCannabinoids, Insomnia, and Other Sleep Disorders
Lavender, I., McGregor, I. S., Suraev, A. S., Grunstein, R. R., & Hoyos, C. M. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.04.151 · Cited by 57
Wong, S., Chan, W.-S., & Cheung, C. W. (2020) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-020-09905-y · Cited by 48
Cannabis and cannabidiol (CBD) for the treatment of fibromyalgia
Berger, A. A., Keefe, J., Winnick, A. A., Gilbert, E., Eskander, J. P., Yazdi, C., Kaye, A. D., Viswanath, O., & Urits, I. (2020) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2020.08.010 · Cited by 66
Campbell, G., Stockings, E., & Nielsen, S. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-018-0960-9 · Cited by 58
Hossain, M. Z., Ando, H., Unno, S., & Kitagawa, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041423 · Cited by 63
McCall, C., & McCall, W. V. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0302-y · Cited by 52
“No objective measure was reported [32].”
Management of Fibromyalgia Syndrome: Review of Evidence
Okifuji, A., & Hare, B. D. (2013) · Pain and Therapy · doi:10.1007/s40122-013-0016-9 · Cited by 49
“[102] compared nabilone to amitriptyline in a crossover trial where patients received a 2-week trial of each drug with a 2-week washout in between.”
MethodSafety and Efficacy of Medicinal Cannabis in the Treatment of Fibromyalgia: A Systematic Review
Kurlyandchik, I., Tiralongo, E., & Schloss, J. M. (2020) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2020.0331 · Cited by 60
“35 Ware et al. 36 used the Insomnia Severity Index (ISI) and the Leeds Sleep Evaluation Questionnaire (LSEQ); short-form Profile of Mood States, FIQ, and global satisfaction with the treatment by using a simple yes/no scale.”
InfluentialCannabis dosing and administration for sleep: a systematic review
Velzeboer, R., Malas, A., Boerkoel, P., Cullen, K., Hawkins, M., Roesler, J., & Lai, W. W.-K. (2022) · SLEEP · doi:10.1093/sleep/zsac218 · Cited by 62
Is There Any Clinically Relevant Cannabinoid-Induced Analgesia?
Kraft, B. (2012) · Pharmacology · doi:10.1159/000337376 · Cited by 50
Suraev, A. S., Grunstein, R. R., Marshall, N. S., D'Rozario, A. L., Gordon, C. J., Bartlett, D. J., WONG, K. K. H., Yee, B. J., Vandrey, R. G., Irwin, C. G., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-034421 · Cited by 54
“…synthetic THC (nabilone) showed improvements in subjective sleep quality in patients with post-traumatic stress disorder (PTSD) 54 55 and fibromyalgia, 56 while CBD was found to be effective in reducing the frequency of rapid eye movement sleep behaviour disorder events in Parkinson’s disease.”
Bourke, S. L., Schlag, A. K., O’Sullivan, S. E., Nutt, D. J., & Finn, D. P. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108216 · Cited by 55
Spanagel, R., & Bilbao, A. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108680 · Cited by 43
“…(9 RCTs (n = 728)) (Wade et al., 2003; Zajicek et al., 2003; Svendsen et al., 2004; Pinsger et al., 2006; Frank et al., 2008; Narang et al., 2008; Ware et al., 2010; Pini et al., 2012; van Amerongen et al., 2018), followed by 18% drug dependent patients (2 RCTs (n = 182)) (Bisaga et al., 2015;…”
Prospects for the Use of Cannabinoids in Psychiatric Disorders
Graczyk, M., Łukowicz, M., & Dzierżanowski, T. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.620073 · Cited by 51
“Numerous studies on managing chronic pain, fibromyalgia, and multiple sclerosis report improved sleep in patients, though (67, 68).”
BackgroundSubstance-related disorders: A review of prevalence and correlates among patients with chronic pain
Martel, M. O., Shir, Y., & Ware, M. A. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.06.032 · Cited by 49
Self-citationMedical cannabis: Another piece in the mosaic of autoimmunity?
Katz, D., Katz, I., Porat‐Katz, B., & Shoenfeld, Y. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.568 · Cited by 41
2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome
Fitzcharles, M., Ste‐Marie, P. A., Goldenberg, D. L., Abbey, S. E., Choinière, M., Ko, G. D., Moulin, D. E., Panopalis, P., Proulx, J., & Shir, Y. (2012) · Cited by 53
Self-citationCannabis for Chronic Pain: A Rapid Systematic Review of Randomized Control Trials
Longo, R., Oudshoorn, A., & Befus, D. (2021) · Pain Management Nursing · doi:10.1016/j.pmn.2020.11.006 · Cited by 39
Cannabis for the Treatment of Fibromyalgia: A Systematic Review
Strand, N. H., Maloney, J. A., Kraus, M. B., Wie, C. S., Turkiewicz, M., Gomez, D. A., Adeleye, O., & Harbell, M. W. (2023) · Biomedicines · doi:10.3390/biomedicines11061621 · Cited by 43
“Treatments were administered as a pill, oil [16,18], smoke [14], or”
InfluentialErgisi, M., Erridge, S., Harris, M., Kawka, M., Nimalan, D., Salazar, O., Loupasaki, K., Ali, R., Holvey, C., Coomber, R., et al. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2020640 · Cited by 42
“similarly found that nabilone, a synthetic THC analog, resulted in greater improvements to sleep compared to amitriptyline in patients with fibromyalgia [54].”
ResultShould doctors prescribe cannabinoids?
Farrell, M., Buchbinder, R., & Hall, W. (2014) · BMJ · doi:10.1136/bmj.g2737 · Cited by 46
Cannabis for Pain and Headaches: Primer
Kim, P. S., & Fishman, M. A. (2017) · Current Pain and Headache Reports · doi:10.1007/s11916-017-0619-7 · Cited by 40
“Neuropathic pain N= 42 Crossover 8 h VAS Decrease p .0004 2 active grp equal Ware et al., 2010 Cannabis (9.4”
BackgroundInfluentialSodium oxybate for the treatment of fibromyalgia
Staud, R. M. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.589836 · Cited by 42
Isahq, M. S., Afridi, M. S., Ali, J., Hussain, M. M., Ahmad, S., & Kanwal, F. (2015) · Asian Pacific Journal of Tropical Disease · doi:10.1016/s2222-1808(15)60953-7 · Cited by 39
“Nabilone was compared by one trial and compared with amitriptyline[27], while all further studies were placebo controlled.”
de Souza Nascimento, S., DeSantana, J. M., Nampo, F. K., Ribeiro, Ê. A. N., da Silva, D. L., Araújo-Júnior, J. X., da Silva Almeida, J. R. G., Bonjardim, L. R., de Souza Araújo, A. A., & Quintans-Júnior, L. J. (2013) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2013/149468 · Cited by 35
“[22] Nabilone/oral 29 10 weeks Sleep disruption Pain Quality of life Mood ISI LSEQ MPQ”
BackgroundMethodResultInfluentialWeighing the balance: how analgesics used in chronic pain influence sleep?
Bohra, M., Kaushik, C., Temple, D., Chung, S. A., & Shapiro, C. M. (2014) · British Journal of Pain · doi:10.1177/2049463714525355 · Cited by 34
Alagbonsi, A. I., & Olayaki, L. A. (2017) · Middle East Fertility Society Journal · doi:10.1016/j.mefs.2016.12.004 · Cited by 36
Possible therapeutic applications of cannabis in the neuropsychopharmacology field
Fernández‐Ruíz, J., Galve‐Roperh, I., Sagredo, O., & Guzmán, M. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.01.013 · Cited by 39
Cannabis-Based Medicines and Medical Cannabis in the Treatment of Nociplastic Pain
Fitzcharles, M., Petzke, F. W., Tölle, T. R., & Häuser, W. (2021) · Drugs · doi:10.1007/s40265-021-01602-1 · Cited by 40
“24), but without differences for pain, mood or quality of life [31] (No ITT-analysis).”
BackgroundSelf-citationCannabis and anticancer drugs: societal usage and expected pharmacological interactions – a review
Bouquié, R., Deslandes, G., Mazaré, H., Cogné, M., Mahé, J., Grégoire, M., & Jolliet, P. (2018) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12373 · Cited by 40
Medical cannabis and cannabinoids in rheumatology: where are we now?
Sarzi‐Puttini, P., Batticciotto, A., Atzeni, F., Bazzichi, L. M., Franco, M. D., Salaffi, F., Marotto, D., Ceribelli, A., Ablin, J. N., & Häuser, W. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1665997 · Cited by 38
“In the literature, there are a limited number of studies on adverse events associated with the use of therapeutic cannabis [85].”
BackgroundDiep, C., Tian, C., Vachhani, K., Won, C. H. J., Wijeysundera, D. N., Clarke, H. A., Singh, M., & Ladha, K. S. (2021) · Regional Anesthesia & Pain Medicine · doi:10.1136/rapm-2021-103161 · Cited by 33
“23 26 Increasing prevalence of both cannabis use and sleep deprivation in the population is a potential cause for concern.”
Priority Considerations for Medicinal Cannabis-Related Research
Bonn-Miller, M., Pollack, C., Casarett, D., Dart, R., Elsohly, M., Good, L. I., Guzmán, M., Hanuš, L., Hill, K., Huestis, M., et al. (2019) · Cannabis and Cannabinoid Research · doi:10.1089/can.2019.0045 · Cited by 31
Self-citationCannabidiol Product Dosing and Decision-Making in a National Survey of Individuals with Fibromyalgia
Boehnke, K. F., Gagnier, J. J., Matallana, L. K., & Williams, D. A. (2021) · Journal of Pain · doi:10.1016/j.jpain.2021.06.007 · Cited by 39
Ste‐Marie, P. A., Fitzcharles, M., Gamsa, A., Ware, M. A., & Shir, Y. (2012) · Arthritis Care & Research · doi:10.1002/acr.21732 · Cited by 34
“In the second study, our group reported that nabilone performed equally to amitriptyline for effect on sleep (27).”
BackgroundSelf-citation
Metadata
- Authors
- Ware, M. A., Fitzcharles, M.-A., Joseph, L., & Shir, Y.
- Affiliations
- McGill University Health Centre (CA)
- McGill University (CA)
- Corresponding author
- Ware, Mark A.
- Shir, Yoram
- Venue
- Anesthesia & Analgesia
- Published
- 2010-02
- Volume
- 110
- Issue
- 2
- Pages
- 604-610
- ISSN
- 0003-2999 (ISSN-L)
- OpenAlex
- W1998257682
- Semantic Scholar
- 5500e899e3f0414ac5d1d0defccd310ff047ba85
- Cited by
- 324
- References
- 34
- Citations by year
- 2026: 12 · 2025: 36 · 2024: 22 · 2023: 15 · 2022: 34 · 2021: 31 · 2020: 29 · 2019: 13 · 2018: 17 · 2017: 21 · 2016: 21 · 2015: 13 · 2014: 21 · 2013: 11 · 2012: 14
- FWCI
- 9.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Anesthesia & Analgesia (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Fibromyalgia and Chronic Fatigue Syndrome Research
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Keywords
- nabilone, fibromyalgia, insomnia, sleep quality, cannabis, synthetic cannabinoids, amitriptyline, chronic pain, adverse events, drug safety and efficacy
- MeSH terms
- Adult, Aged, Amitriptyline, Antidepressive Agents, Double-Blind Method, Female, Fibromyalgia, Humans, Sleep Initiation and Maintenance Disorders, Male, Middle Aged, Pain Measurement, Sleep, Dronabinol, Anti-Anxiety Agents, Patient Satisfaction, Cross-Over Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.